Mainz Biomed NV Reports Positive Results for BloodBased Pancreatic Cancer Screening Test in Feasibility Study

Reuters

2025/10/08

Mainz Biomed NV Reports Positive Results for BloodBased Pancreatic Cancer Screening Test in Feasibility Study

Mainz Biomed NV has announced positive topline results from a feasibility study evaluating a non-invasive blood-based screening test for the early detection of pancreatic cancer. The study assessed 18 proprietary mRNA biomarkers and identified a panel that demonstrated 100% sensitivity and 95% specificity in distinguishing pancreatic cancer patients from healthy controls within a 30-subject cohort. The results confirmed the clinical accuracy and utility of the biomarkers, and the company plans to initiate a larger clinical study using banked retrospective samples to further evaluate biomarker performance across different stages of pancreatic cancer. This future study will utilize next-generation sequencing technologies and is part of Mainz Biomed's broader strategy to develop accessible molecular diagnostics for early cancer detection.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001131958-en) on October 08, 2025, and is solely responsible for the information contained therein.

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2573250289"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2573250289\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2573250289?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-08 21:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2573250289","market":"us","top_or_hot":-1,"title":"Mainz Biomed NV Reports Positive Results for BloodBased Pancreatic Cancer Screening Test in Feasibility Study","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mainz Biomed NV Reports Positive Results for BloodBased Pancreatic Cancer Screening Test in Feasibility Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Mainz Biomed NV has announced positive topline results from a feasibility study evaluating a non-invasive blood-based screening test for the early detection of pancreatic cancer. The study assessed 18 proprietary mRNA biomarkers and identified a panel that demonstrated 100% sensitivity and 95% specificity in distinguishing pancreatic cancer patients from healthy controls within a 30-subject cohort. The results confirmed the clinical accuracy and utility of the biomarkers, and the company plans to initiate a larger clinical study using banked retrospective samples to further evaluate biomarker performance across different stages of pancreatic cancer. This future study will utilize next-generation sequencing technologies and is part of Mainz Biomed's broader strategy to develop accessible molecular diagnostics for early cancer detection.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001131958-en) on October 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Mainz Biomed NV Reports Positive Results for BloodBased Pancreatic Cancer Screening Test in Feasibility Study</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMainz Biomed NV Reports Positive Results for BloodBased Pancreatic Cancer Screening Test in Feasibility Study\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-08 21:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Mainz Biomed NV Reports Positive Results for BloodBased Pancreatic Cancer Screening Test in Feasibility Study\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Mainz Biomed NV has announced positive topline results from a feasibility study evaluating a non-invasive blood-based screening test for the early detection of pancreatic cancer. The study assessed 18 proprietary mRNA biomarkers and identified a panel that demonstrated 100% sensitivity and 95% specificity in distinguishing pancreatic cancer patients from healthy controls within a 30-subject cohort. The results confirmed the clinical accuracy and utility of the biomarkers, and the company plans to initiate a larger clinical study using banked retrospective samples to further evaluate biomarker performance across different stages of pancreatic cancer. This future study will utilize next-generation sequencing technologies and is part of Mainz Biomed's broader strategy to develop accessible molecular diagnostics for early cancer detection.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001131958-en) on October 08, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B64PRP62.GBP","symbol_name":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251008:nNDL1S70Qx:1","article_id":"2573250289","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2573250289","pubTimestamp":1759928436,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Mainz Biomed NV has announced positive topline results from a feasibility study evaluating a non-invasive blood-based screening test for the early detection of pancreatic cancer. The study assessed 18 proprietary mRNA biomarkers and identified a panel that demonstrated 100% sensitivity and 95% specificity in distinguishing pancreatic cancer patients from healthy controls within a 30-subject cohort. The results confirmed the clinical accuracy and utility of the biomarkers, and the company plans to initiate a larger clinical study using banked retrospective samples to further evaluate biomarker performance across different stages of pancreatic cancer. This future study will utilize next-generation sequencing technologies and is part of Mainz Biomed's broader strategy to develop accessible molecular diagnostics for early cancer detection.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and time","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","BK4112":"金融交易所和数据","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","NDAQ":"纳斯达克OMX交易所","MYNZ":"Mainz Biomed NV","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC"},"translate_title":"Mainz Biomed NV在可行性研究中报告了基于血液的胰腺癌筛查测试的阳性结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYNZ":0.9,"NDAQ":0.9},"content_text":"Mainz Biomed NV Reports Positive Results for BloodBased Pancreatic Cancer Screening Test in Feasibility Study\n    \n\n        Mainz Biomed NV has announced positive topline results from a feasibility study evaluating a non-invasive blood-based screening test for the early detection of pancreatic cancer. The study assessed 18 proprietary mRNA biomarkers and identified a panel that demonstrated 100% sensitivity and 95% specificity in distinguishing pancreatic cancer patients from healthy controls within a 30-subject cohort. The results confirmed the clinical accuracy and utility of the biomarkers, and the company plans to initiate a larger clinical study using banked retrospective samples to further evaluate biomarker performance across different stages of pancreatic cancer. This future study will utilize next-generation sequencing technologies and is part of Mainz Biomed's broader strategy to develop accessible molecular diagnostics for early cancer detection.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mainz Biomed NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW1001131958-en) on October 08, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}